Wedbush Has Lowered Expectations for Aprea Therapeutics (NASDAQ:APRE) Stock Price

Posted by Brian Himes on May 14th, 2026

Aprea Therapeutics (NASDAQ:APRE – Get Free Report) had its price objective lowered by stock analysts at Wedbush from $7.00 to $6.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

A number of other research firms have also recently weighed in on APRE. HC Wainwright lowered their price target on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Monday, April 20th. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Finally, Oppenheimer began coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aprea Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.07.

View Our Latest Stock Report on Aprea Therapeutics

Aprea Therapeutics Price Performance

Shares of NASDAQ:APRE opened at $0.90 on Thursday. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.22. The company’s fifty day moving average price is $0.82 and its 200 day moving average price is $0.92. The firm has a market capitalization of $11.18 million, a P/E ratio of -0.46 and a beta of 1.48.

Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. On average, sell-side analysts anticipate that Aprea Therapeutics will post -0.87 EPS for the current year.

Institutional Trading of Aprea Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC grew its stake in Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares during the period. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics in the 4th quarter valued at about $40,000. Finally, DRW Securities LLC bought a new position in shares of Aprea Therapeutics during the fourth quarter worth about $103,000. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.